Pneumocystis jirovecii Pneumonia in Patients Without HIV Infection

In a retrospective study, risk factors included hematologic malignancy, solid tumor, inflammatory disease, solid-organ transplant, and vasculitis.

Prevention strategies for Pneumocystis jirovecii pneumonia (PJP) among patients with HIV infection are well established. However, there is no consensus regarding PJP prophylaxis in HIV-uninfected individuals. Although the American Thoracic Society advises prophylaxis for patients taking prednisone at doses >20 mg per day for >1 month, this recommendation is not evidence based.

Investigators recently performed a retrospective analysis of patients with pneumocystosis admitted to a tertiary-care hospital in France between January 1990 and June 2010. Among these 293 individuals, 154 (53%) tested negative for HIV infection. The proportion of patients admitted to the intensive care unit (ICU; 52% vs. 28%) and the ICU mortality rate (53% vs. 15%) w…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Pneumocystis jirovecii Pneumonia in Patients Without HIV Infection

Topics

Reviewing Author